Evogene Ltd.

Foreign Filer Report • Sep 10, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Evogene Investor Presentation.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: September 10, 2025

By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

Exhibit 99.1

e E

e

FORWARD LOOKING STATEMENT

This presentation contains flowerd-looking to future events, and Evogene Ltd. (the "Company") may from time to time make other stationing, regarding our outlook for future financial or operating results and/or other matters regarding or that are considered "forward-looking statements" as defined in the U.S. Private Securities Liligation Reform Ast of 1995 (the "PSLR4") and other securities laws, as amended. Statements that are not statements of historical fact may be forward-icoling statements. Such forward-looking statements may be identified by the use of such words as "believe", "thicipose", "should", "planned", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization effors and timing product development and launches, estimated market sizes and millestones, pipaline, and technology,

Such statements are based on current expections and assumptions, describe apinions about future events, involve owners, involve owners, involve owners, involve owners, involv risks and uncertainties which are difficult to precises of future performance. Resders are cusioned that certain important. foctors may affect the Companys actual results to differ materially from any forward-looking stagements that may be mode in this presentation. Therefore, actual future results, performance or ochievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of fectors, many of which are beyond our control, including, without limitation, the current was between israel and Ary further advarse impact that it may have on economic activity in israel due to the calling up of a large number of reserve saidlers or the incurrence of debt to pay for the high cost of the war, and any accompanying future uncertaintes for the security of the Company's operations in southern local, as well as those additional foctors described in greater detailln Evogeners Annual Report on Form 20-F and in other reports Evogine files with and furnishes to the Israel Securities Authority and the U.S. Securites and Exchange Commission, including those factors under the heading "Risk Factors".

Everpt as required by applicable securities laws, we disclaim or commitment to update any information contained in this presentation or to publicly release the results of any statements that may be made to reflect future events or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering decument, nor does it constitute or form part of any invitation or offer to sall, or any solicitation of any invitation or offer to purchase or subscribes of the Company, nor shall the information or any part of it or the fost of its distribution form the basis of, or be relied on in connection with any action contract or commisms relating therett or to the securities of the Company.

The trademarks included herein are the property of the cannot and are used for reference purposes any. Such use should not be construed as an endorsement of our products or services.

2 evogene

THERE IS A GAP BETWEEN REAL-WORLD CHALLENGES AND INNOVATIVE SOLUTIONS

THE MULTI-PARAMETER OPTIMIZATION CHALLENGE

Creating a molecule that will succeed through all development phases requires balancing in advance multiple, often competing, parameters

THE CHALLENGE FOR TRADITIONAL METHODS:

• · Optimization typically limited to a small number of parameters
• · Cannot address multiple parameters simultaneously
• · Requires lengthy, resource intensive iterative cycles

10 evogene

GOOGLE CLOUD x EVOGENE BREAKING NEW GROUND IN AI-FIRST MOLECULE DESIGN

TRANSFORMATIVE PARTNERSHIP

Combining Evogene's proprietary Al foundation model, with Google Cloud's world-class infrastructure to scale revolutionary molecular discovery

ACCELERATED INNOVATION

Google's infrastructure enabled efficient use of a massive dataset starting with millions and ultimately reaching a training set of approximately 38 billion molecular structures

3x IMPROVED ACCURACY

Optimization across multiple-parameters reached 90% precision (vs. 29% in traditional GPT Al-model)

"We're pleased to collaborate with Evogene's innovation in Alpowered molecule design. Their progress with ChemPass Al highlights the strength of pairing advanced AI infrastructure with deep scientific insight. We look forward to seeing the impact of this new model in drug discovery and agriculture."

BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL

DELIVERING REAL-WORLD INNOVATION

THROUGH TWO STRATEGIC MARKET DIVISIONS

15 evOgene

AG ACTIVITY Via AgPlenus A GROWING MARKET WITH PLENTY OF ROOM FOR INNOVATION Increase of pest resistance & regulatory requirements Urgent need for new Modes of Action (MoAs) 3 Decreased rate in discovery of new pesticides due to lack of innovation 17 Company calculation based on: 1) Data Bridge Market Research 2) Fortune Business Insights 3) Data Bridge\$43.3B BROAD SPECTRUM HERBICIDES \$22.2B FUNGICIDES FOR MAJOR DISEASES2 \$22.3B BROAD SPECTRUM INSECTICIDES3

STRATEGIC COLLABORATIONS

"Bringing together AgPlenus" expertise with Bayer's CropKey approach to crop protection innovation will help accelerate the delivery of essential, sustainable, and affordable solutions to farmers and set a new benchmark in the industry."

Rachel Rama, Head of Small Molecules, Crop Science division

Development of new sustainable Mode-of-Action broad spectrum, herbicide Demonstrated high weed control efficacy and good tolerance in corn

*The collaboration with AgPlenus has accelerated the identification of a class of herbicide chemistry that targets a new modeof-action for weed control, something the industry has been lacking for decades."

nontreato

Vid Hegde, Former VP of Crop Protection Discovery and Development

Development of novel herbicides

Demonstrated weed growth reduction in post emergence application

19 evOgene

INTERNAL PIPELINE WHEAT BLOTCH

DISRUPTING A \$1.2B PROBLEM AT RECORD SPEED

· 70% of EU fungicide usage in wheat is for Wheat Blotch1 · EU market alone >\$1.2B annually1 · Widespread resistance to current top products ("Strobilurins") with 2024 sales of \$4.59B2

APTF-4 PRESENTS STRONG POTENTIAL FOR REAL-WORLD INNOVATION · Shows clear concentrationdependent antifungal efficacy

1000 1000

001 6.1 10 10

a lumb

• · Ongoing optimization to enhance potency
• · 18 months from target to optimized hit

20 evOgene allersonal allerser 2007 a letel & cowth traights

GROWING OPPORTUNITY IN AI-DRUG DISCOVERY

CHEMPASS AI: DRIVING HIGHER CUMULATIVE PROBABILITY OF SUCCESS

THE KEY FOR SUCCESS -STRATEGIC PARTNERSHIPS / INTERNAL EXPERTISE TAILORED TO EACH CHALLENGE & OPTIMIZED FOR SUCCESS

PHARMA DIVISION

SHOWCASING SYSTEM CAPABILITIES: MOLECULAR GLUE CASE STUDY

PARTNERSHIP WITH LEADING BIOTECH

To develop first-in-class molecular glue therapeutics

NOVEL TARGET:

Protein-protein interaction, considered highly challenging

CHEMPASS AI GENERATED 150 MOLECULES WITH PROMISING RESULTS

• · 100% novelty (not in DBs or patents)
• · Synthesizability confirmed
• · 93% uniqueness
• · 92% validity (chemically viable)
• · 6x improvement in binding prediction accuracy

26 evOgene

REAL-WORLD INNOVATION Unique technology to create novel small molecules MULTI-PARAMETER OPTIMIZATION Balancing ~20 constrains simultaneously using ChemPass Al AI-FIRST, FROM HIT TO LEAD Integrating proprietary technology across the entire discovery pipeline ev°qene Real-world innovation UNLIMITED INNOVATION Based on ~38B molecule structures HIGHER PROBABILITY OF SUCCESS 9096 of molecules generated meet all predefined parameters PROVEN IN AG PIONEERING IN PHARMA Real-world impact where it matters most